Intel's stock has surged 50% over eight consecutive trading sessions, driven by significant announcements. Analysts believe the company is experiencing a "renewed lease on life" and anticipate further positive developments. This winning streak marks a notable turnaround for Intel.

JPMorgan Chase & Co. has increased its price target for GFL Environmental (NYSE:GFL) from $48.00 to $49.00, while maintaining a "neutral" rating, indicating a potential upside of 13.66% from its previous closing price. This adjustment follows GFL Environmental beating quarterly EPS estimates but missing revenue expectations, with multiple other analysts also offering varied recommendations and price targets. The company's stock currently trades around $43.11 with a P/E ratio of 6.33 and an average analyst target of $56.78, signifying a "Moderate Buy" consensus.

JPMorgan Chase & Co. has increased its price target for Republic Services (NYSE:RSG) to $245.00 from $233.00, maintaining a "neutral" rating. This new target suggests a potential upside of approximately 14.5% from the previous closing price. The company recently reported strong quarterly earnings, beating consensus estimates with $1.76 EPS and also provided a positive FY2026 guidance.

Diamondback Energy Inc. announced the pricing for tender offers to purchase its outstanding 4.400% Senior Notes due 2051 and 4.250% Senior Notes due 2052. The company will pay $825.60 per $1,000 principal for the 2051 notes and $802.42 per $1,000 principal for the 2052 notes, with the offers expiring on April 10, 2026. The transaction is expected to settle on April 13, 2026, involving major financial institutions as dealer managers.

TrustCo Bank Corp NY (TRST) announced it will release its first quarter 2026 results after the market closes on April 21, 2026. A conference call to discuss these results will be held at 9:00 a.m. Eastern Time on April 22, 2026, with details provided for participation and replay. The earnings press release and other company information will be available on TrustCo's Investor Relations website.

China's National Medical Products Administration has approved Amgen's tarlatamab (Imdelltra) for adult patients with extensive-stage small cell lung cancer that has progressed after platinum-based chemotherapy. This approval, following FDA approval in 2025, is based on Phase II DeLLphi-301 study data showing significant objective response rates and median overall survival. The article also discusses a 23andMe study on genetic predictors for GLP-1 weight loss efficacy and side effects, and an interview with Phenomix CEO Mark Bagnall regarding the complex realities and hidden costs of GLP-1 usage.

Spyre Therapeutics will host a conference call on April 13, 2026, to announce the topline results from Part A induction of its SKYLINE trial for SPY001 in moderate-to-severe ulcerative colitis patients. This announcement follows a series of steady advancements in Spyre's pipeline and corporate agenda, including strong 2025 financial results and multiple planned proof-of-concept readouts for 2026. The company holds a significant cash balance and has an active S-3 shelf registration for potential future financing.

Illinois Tool Works Inc. (ITW) announced it will release its first quarter 2026 results on Thursday, April 30, 2026, at 7:00 a.m. CDT. Following the release, the company will host an earnings webcast at 9:00 a.m. CDT, providing details for participants to join. Presentation materials and an audio webcast replay will be available on their investor relations website, with an audio-only replay accessible for a limited time via dial-in numbers.

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK) for $53.00 per share in cash. KSF is evaluating whether the consideration and the process leading to it are adequate, suspecting the offer might undervalue the company. Shareholders are encouraged to contact KSF if they believe the transaction undervalues Terns Pharmaceuticals or to discuss their legal rights.

Sysco Corp., a leading U.S. foodservice distributor, is well-positioned for steady growth due to its nationwide network and strong presence in the resilient $300+ billion U.S. foodservice market. The company's business model, which includes a vast distribution network, vertical integration, and a focus on premium ingredients, provides stability for investors despite economic fluctuations. Analysts generally view Sysco favorably for its defensive qualities, dividend growth, and potential for margin expansion, recommending it for long-term portfolios.